Zur Kurzanzeige

dc.creatorBonovas, S.en
dc.creatorNikolopoulos, G.en
dc.creatorBagos, P.en
dc.date.accessioned2015-11-23T10:24:00Z
dc.date.available2015-11-23T10:24:00Z
dc.date.issued2013
dc.identifier10.1111/bcp.12135
dc.identifier.issn0306-5251
dc.identifier.urihttp://hdl.handle.net/11615/26355
dc.description.abstractAimA growing body of evidence suggests that bisphosphonates may have chemopreventive potential against colorectal cancer. Our aim was to examine this association through a meta-analysis of observational studies. MethodsA comprehensive search for relevant articles published up to October 2012 was performed, reviews of each study were conducted and data were abstracted. Prior to meta-analysis, the studies were evaluated for publication bias and heterogeneity. Pooled relative risk (RR) estimates and 95% confidence intervals (CIs) were calculated using the random effects and the fixed effects models. Subgroup and sensitivity analyses were also performed. ResultsEight large population-based epidemiological studies (one case-control, two nested case-control analyses within a cohort and five cohort studies), involving more than 630000 participants, contributed to the analysis. We found no evidence of publication bias. However, significant heterogeneity was detected among the cohort studies. The analysis revealed a significant protective association between bisphosphonate use and colorectal cancer risk (fixed RR = 0.85, 95% CI 0.80, 0.90, random RR = 0.85, 95% CI 0.75, 0.96). When the analysis was stratified into subgroups according to study design, the association was inverse in both case-control and cohort studies, but only in the former was it statistically significant. The sensitivity analysis confirmed the stability of our results. Furthermore, we found evidence for a dose effect; Long term bisphosphonate use was associated with a 27% decrease in the risk of developing colorectal cancer as compared with non-use (RR = 0.73, 95% CI 0.57, 0.93). ConclusionOur findings support a protective effect of bisphosphonates against colorectal cancer. However, further evidence is warranted.en
dc.sourceBritish Journal of Clinical Pharmacologyen
dc.source.uri<Go to ISI>://WOS:000326245400003
dc.subjectbisphosphonatesen
dc.subjectcolorectal canceren
dc.subjectmeta-analysisen
dc.subjectPOSTMENOPAUSAL WOMENen
dc.subjectCOLON-CANCERen
dc.subjectORAL BISPHOSPHONATESen
dc.subjectZOLEDRONICen
dc.subjectACIDen
dc.subjectSUBSEQUENT RISKen
dc.subjectBONE MASSen
dc.subjectOSTEOPOROSISen
dc.subjectTHERAPYen
dc.subjectDENSITYen
dc.subjectCELLSen
dc.subjectPharmacology & Pharmacyen
dc.titleBisphosphonate use and risk of colorectal cancer: a systematic review and meta-analysisen
dc.typejournalArticleen


Dateien zu dieser Ressource

DateienGrößeFormatAnzeige

Zu diesem Dokument gibt es keine Dateien.

Das Dokument erscheint in:

Zur Kurzanzeige